CINXE.COM

<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:media="http://search.yahoo.com/mrss/" > <channel> <title>Pharmafile</title> <atom:link href="https://pharmafile.com/feed/" rel="self" type="application/rss+xml" /> <link>https://pharmafile.com</link> <description>Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, insights, analysis and events.</description> <lastBuildDate>Wed, 02 Apr 2025 16:29:17 +0000</lastBuildDate> <language>en-GB</language> <sy:updatePeriod> hourly </sy:updatePeriod> <sy:updateFrequency> 1 </sy:updateFrequency> <site xmlns="com-wordpress:feed-additions:1">218578772</site> <item> <title>GRI Bio announces two global patents granted for Europe and Japan</title> <link>https://pharmafile.com/news/gri-bio-announces-two-global-patents-granted-for-europe-and-japan/</link> <dc:creator><![CDATA[Ella Day]]></dc:creator> <pubDate>Wed, 02 Apr 2025 16:28:59 +0000</pubDate> <category><![CDATA[autoimmune diseases]]></category> <category><![CDATA[biotech]]></category> <category><![CDATA[fibrotic diseases]]></category> <category><![CDATA[GRI Bio]]></category> <category><![CDATA[inflammatory diseases]]></category> <category><![CDATA[patent]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&p=40406</guid> <description><![CDATA[GRI Bio, a biotech company that specialises in treatment for inflammatory, fibrotic and autoimmune diseases, has announced that two global patents have been granted in Europe and Japan. The first is a European patent titled, ‘Oxygenated Amino- or Ammonium Containing Sulfonic Acid, Phosphonic Acid and Carboxylic Acid Derivatives and Their Medical Use.’ It aims to […] The post <a rel="nofollow" href="https://pharmafile.com/news/gri-bio-announces-two-global-patents-granted-for-europe-and-japan/">GRI Bio announces two global patents granted for Europe and Japan</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>. ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40406</post-id> </item> <item> <title>Usama Dar appointed as chief product and technology officer at CluePoints</title> <link>https://pharmafile.com/appointments/usama-dar-appointed-as-chief-product-and-technology-officer-at-cluepoints/</link> <dc:creator><![CDATA[Ella Day]]></dc:creator> <pubDate>Wed, 02 Apr 2025 16:10:36 +0000</pubDate> <category><![CDATA[clinical trial analysis]]></category> <category><![CDATA[cluepoints]]></category> <category><![CDATA[pharma]]></category> <category><![CDATA[research and development]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=appointments&p=40409</guid> <description><![CDATA[CluePoints has appointed Usama Dar as its new chief product and technology officer, effective 1 April 2025. This follows Dar’s leadership and development of product and R&D teams at the company. Dar has held leadership roles at organisations such as Westwing, Sciensus, Elsevier, The Guardian and Huawei. He has experience in eCommerce, software as a […] The post <a rel="nofollow" href="https://pharmafile.com/appointments/usama-dar-appointed-as-chief-product-and-technology-officer-at-cluepoints/">Usama Dar appointed as chief product and technology officer at CluePoints</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>. ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40409</post-id> </item> <item> <title>Dupixent approved as first biologic medicine in Japan for COPD patients</title> <link>https://pharmafile.com/news/dupixent-approved-as-the-first-biologic-medicine-in-japan-for-copd-patients/</link> <dc:creator><![CDATA[Ella Day]]></dc:creator> <pubDate>Wed, 02 Apr 2025 14:01:07 +0000</pubDate> <category><![CDATA[biotech]]></category> <category><![CDATA[COPD]]></category> <category><![CDATA[Regeneron]]></category> <category><![CDATA[respiratory disease]]></category> <category><![CDATA[Sanofi]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&p=40401</guid> <description><![CDATA[The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults, whose disease is inadequately controlled by existing therapy. The approval in Japan was based on data from the BOREAS phase 3 study conducted by Sanofi and Regeneron. […] The post <a rel="nofollow" href="https://pharmafile.com/news/dupixent-approved-as-the-first-biologic-medicine-in-japan-for-copd-patients/">Dupixent approved as first biologic medicine in Japan for COPD patients</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>. ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40401</post-id> </item> <item> <title>ADHD coach and breathwork experts to run workshop for ADHD management</title> <link>https://pharmafile.com/news/adhd-coach-and-breathwork-experts-to-run-a-breathwork-focused-workshop-for-adhd-management/</link> <dc:creator><![CDATA[Ella Day]]></dc:creator> <pubDate>Wed, 02 Apr 2025 13:46:00 +0000</pubDate> <category><![CDATA[ADHD]]></category> <category><![CDATA[healthcare]]></category> <category><![CDATA[mental health]]></category> <category><![CDATA[nervous system]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&p=40395</guid> <description><![CDATA[ADHD coach John Harrington and breathwork facilitator Martin O’Toole will collaborate on ‘Breathwork for ADHD and Beyond’, a breathwork-orientated session for people with ADHD, and neurodivergent individuals more broadly. The two-hour session takes place on Sunday 13 April at We The Conscious studio in Hackney Downs, London, UK. In the first hour, Harrington will discuss […] The post <a rel="nofollow" href="https://pharmafile.com/news/adhd-coach-and-breathwork-experts-to-run-a-breathwork-focused-workshop-for-adhd-management/">ADHD coach and breathwork experts to run workshop for ADHD management</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>. ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40395</post-id> </item> <item> <title>Rybelsus found to reduce major adverse cardiovascular events in Novo Nordisk trial</title> <link>https://pharmafile.com/news/rybelsus-found-to-reduce-major-adverse-cardiovascular-events-in-novo-nordisk-trial/</link> <dc:creator><![CDATA[Ella Day]]></dc:creator> <pubDate>Tue, 01 Apr 2025 16:19:59 +0000</pubDate> <category><![CDATA[cardiometabolic diseases]]></category> <category><![CDATA[Novo Nordisk]]></category> <category><![CDATA[research and development]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&p=40392</guid> <description><![CDATA[Novo Nordisk announced results from its SOUL cardiovascular outcomes trial. Rybelsus (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD). The new phase 3b data was presented at the American College of Cardiology’s (ACC) Annual Scientific Session […] The post <a rel="nofollow" href="https://pharmafile.com/news/rybelsus-found-to-reduce-major-adverse-cardiovascular-events-in-novo-nordisk-trial/">Rybelsus found to reduce major adverse cardiovascular events in Novo Nordisk trial</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>. ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40392</post-id> </item> <item> <title>Corcept’s relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint</title> <link>https://pharmafile.com/news/corcept-therapeutics-relacoinent-trial-in-patients-with-platinum-resistant-ovarian-cancer-meets-primary-endpoint/</link> <dc:creator><![CDATA[Ella Day]]></dc:creator> <pubDate>Tue, 01 Apr 2025 14:32:06 +0000</pubDate> <category><![CDATA[Corcept Therapeutics]]></category> <category><![CDATA[ovarian cancer]]></category> <category><![CDATA[research and development]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&p=40381</guid> <description><![CDATA[Corcept Therapeutics announced that relacorilant plus nab-paclitaxel met its primary endpoint of improved progression-free survival in ROSELLA, the company’s phase 3 trial of the therapy. The ROSELLA trial enrolled 381 patients with platinum-resistant ovarian cancer across sites internationally. Patients were randomised 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone. ROSELLA has dual primary […] The post <a rel="nofollow" href="https://pharmafile.com/news/corcept-therapeutics-relacoinent-trial-in-patients-with-platinum-resistant-ovarian-cancer-meets-primary-endpoint/">Corcept’s relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>. ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40381</post-id> </item> <item> <title>Secarna Pharmaceuticals to announce positive new data at cancer research conference</title> <link>https://pharmafile.com/news/secarna-pharmaceuticals-to-announce-positive-new-data-at-cancer-research-conference/</link> <dc:creator><![CDATA[Ella Day]]></dc:creator> <pubDate>Tue, 01 Apr 2025 14:22:18 +0000</pubDate> <category><![CDATA[oncology]]></category> <category><![CDATA[research and development]]></category> <category><![CDATA[Secarna Pharmaceuticals]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&p=40379</guid> <description><![CDATA[Secarna Pharmaceuticals will present new preclinical data with its lead programme SECN-15 at the American Association for Cancer Research (AACR) taking place 25 to 30 April 2025 in Chicago, Illinois, US. Data will showcase SECN-15’s potential to significantly improve the efficacy of immune checkpoint inhibitors (ICIs). Secarna is a biopharma company which develops and redefines […] The post <a rel="nofollow" href="https://pharmafile.com/news/secarna-pharmaceuticals-to-announce-positive-new-data-at-cancer-research-conference/">Secarna Pharmaceuticals to announce positive new data at cancer research conference</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>. ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40379</post-id> </item> <item> <title>Qfitlia approved by FDA to treat haemophilia A or B</title> <link>https://pharmafile.com/news/qfitlia-approved-by-fda-to-treat-haemophilia-a-or-b/</link> <dc:creator><![CDATA[Ella Day]]></dc:creator> <pubDate>Mon, 31 Mar 2025 15:36:38 +0000</pubDate> <category><![CDATA[FDA]]></category> <category><![CDATA[haemophilia]]></category> <category><![CDATA[pharma]]></category> <category><![CDATA[Sanofi]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&p=40375</guid> <description><![CDATA[The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran) as the first therapy in the US to treat haemophilia A or B, with or without inhibitors. The approval of the antithrombin-lowering (AT) drug was based on data from the ATLAS phase 3 studies that Sanofi conducted. Sanofi is an international pharma and healthcare […] The post <a rel="nofollow" href="https://pharmafile.com/news/qfitlia-approved-by-fda-to-treat-haemophilia-a-or-b/">Qfitlia approved by FDA to treat haemophilia A or B</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>. ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40375</post-id> </item> <item> <title>Alfred Merz appointed as CEO of ProBioGen</title> <link>https://pharmafile.com/appointments/alfred-merz-appointed-as-ceo-of-probiogen/</link> <dc:creator><![CDATA[Ella Day]]></dc:creator> <pubDate>Mon, 31 Mar 2025 15:17:20 +0000</pubDate> <category><![CDATA[appointment]]></category> <category><![CDATA[biotech]]></category> <category><![CDATA[CEO]]></category> <category><![CDATA[ProBioGen]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=appointments&p=40373</guid> <description><![CDATA[ProBioGen has announced the appointment of Alfred Merz as its chief executive officer (CEO), effective 1 April 2025. Merz, who was previously chief operating officer (COO) and interim CEO, now assumes leadership of the company. Merz has over 30 years’ worth of experience in manufacturing, operations and strategy development. Before joining ProBioGen 2024, he was […] The post <a rel="nofollow" href="https://pharmafile.com/appointments/alfred-merz-appointed-as-ceo-of-probiogen/">Alfred Merz appointed as CEO of ProBioGen</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>. ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40373</post-id> </item> <item> <title>Medidata launches programme to accelerate therapy delivery</title> <link>https://pharmafile.com/news/medidata-launches-programme-to-accelerate-therapy-delivery/</link> <dc:creator><![CDATA[Ella Day]]></dc:creator> <pubDate>Mon, 31 Mar 2025 14:33:13 +0000</pubDate> <category><![CDATA[Medidata]]></category> <category><![CDATA[pharma]]></category> <category><![CDATA[technology]]></category> <guid isPermaLink="false">https://pharmafile.com/?post_type=pharma_news&p=40367</guid> <description><![CDATA[Medidata has announced the launch of its Medidata Site Insights Program – a collection of initiatives intended to foster more effective dialogue between sites and accelerate the delivery of therapies to patients. Medidata, a subsidiary of Dassault Systèmes, is a technology company that provides software as a service (SaaS) solutions for clinical trials, helping life […] The post <a rel="nofollow" href="https://pharmafile.com/news/medidata-launches-programme-to-accelerate-therapy-delivery/">Medidata launches programme to accelerate therapy delivery</a> appeared first on <a rel="nofollow" href="https://pharmafile.com">Pharmafile</a>. ]]></description> <post-id xmlns="com-wordpress:feed-additions:1">40367</post-id> </item> </channel> </rss>